It is the purpose here to review these various aspects of anticoagulant therapy and to discuss the various factors which we consider to be of importance in the practical management of this form of treatment.
Coagulation and thrombosis. The state of the blood within a blood vessel is influenced by the health of the vessel wall, the state of the circulation, and the coagulability of the blood. Alteration in the' vascular endothelium is the primary cause of thrombosis. How this alteration in the vascular endothelium precipitates the process of intravascular coagulation is uncertain. It is believed by some that the adhesion of platelets resulting from the abnormal vascular endothelium sets in motion an interaction of these platelets with a factor in the plasma (thromboplastinogen? Quick, 1951) resulting in the formation of thromboplastin (Fig. I) . As a result of this local reaction, a cycle of events, autocatalytic in nature, leads to a rapidly cumulative, almost explosive, reaction which causes spread oi the thrombosis. This chain reaction is catalyzed by thrombin (Stefanini, Fig. 1. An outline of the coagulation mechanism. The method by which thrombin hastens the production of thromboplastin is uncertain.
1951). Thus the appearance of a small amount of thrombin by the mechanism outlined in Fig. 1 Heparin. Heparin is a naturally occurring anticoagulant which is exceedingly active in vivo. The physiological function of heparin is uncertain, for it ls seldom found naturally in the blood stream, the natural antithronibin activity of plasma being a different entity. It is uncertain how heparin interferes with the normal coagulation mechanism. In the presence of a plasma co-factor heparin and thrombin form a reversible combination 111 which thrombin is inactivated. Probably heparin also interferes with j-he conversion of prothrombin to thrombin (Jorpes, 11)4(5 (Litwins et al., 1951) has not been confirmed (Kennedy & Brown, 1952) Wright, 1949 (Ricketts et al., 1950 ; Rieketts, 1951) .
In common with other polysaccharide sulphuric esters, dextran sulphates have a heparin-like activity. Investigations by Walton (1951) showed that the toxicity of these substances is related to their molecular Weight, and that when the starting material (dextran) is below a certain molecular weight, the sulphuric ester prepared from it is no more toxic than heparin itself in experimental animals. (Walton, 1951) . Ricketts (1952) (Link, 1943-44) (Roderick, 19131) . Dicoumarol has been shown to be the substance ^sponsible for this change (Link, 1943-44 (Jensen & Jensen, 1942 ). It appears also that small amounts of dicoumarol are biologically antagonistic to disproportionately large increases in vitamin K intake (Overman et al., 1942 ; Glavind & Jensen, 1944 Battle et al. (1950) (1950) , by Allen and Hill (1951) , by Hanson et al. (1951) , by Rotter and Meyer (1951) , and by Barker et al. (1952) . . Trials of phenylindanedione in the human subject suggest that the effect is more uniform, the response more rapid, and the recovery more immediate than when dicoumarol is used (Bjerkelund, 1950 ; Blaustein, 1950 ; Blaustein et al., 1950 (Murray et al., 1937) .
Experimental work with dicoumarol has shown that this substance also can be used effectively against thrombosis, which is markedly inhibited in the presence of full dicoumarol effect (Allen et al., 1942 ; Thill et al., 1943 (Wright, 194(5) . Kubik and Wright (1950) (Wright, 1949) (Crafoord, 1941 It is a common belief that pulmonary emboli, occurring in patients with cardiac disease, arise from the right side of the heart. This is in spite of the frequent failure to demonstrate residual clot in this region at autopsy. In post-mortem investigation of 90 cases of pulmonary embolism, 56 of which showed rheumatic heart disease or evidence of recent or previous myocardial infarction, only 12 showed mural thrombi in the right side of the heart, and over 75 per cent of those in whom the leg veins were examined showed thrombosis in these vessels (Carlotti et al., 1947) .
Embolic complications from the left side of the heart are common in myocardial infarction, and the thrombotic complications of this disease rank high among the causes of death. Their presence at autopsy has been assessed as varying from 9.9 per cent (Mintz & Katz, 1947) (Wright, 1946 ; Nichol & Page, 1946 ; Peters et al., 1946) led to a large scale investigation by the American Heart Association (Wright et al., 1948 (Glueck et al-> 1948 ; Parker & Barker, 1948 ; McCall, 1948 ; Schilling, 1950 ; Tulloch & Gilchrist, 1950 (Link, 1943-44) . In a recent review it has been concluded that in man there is a greater tendency to haemorrhage when the prothrombin time has been elevated for some days (Hogben & Allen, 1950 (Shapiro, 1944) , in coronary and cerebral thrombosis (Hines & Kessler, 1945) (Fowler, 1949 (Jorpes, 194(5) .
Control of administration. When heparin is given intravenously in four daily doses of 4,000-12,000 units as described, it is the practice (Bauer, 1946a, b) (Fergusson, 1946 (Bjerkelund, 1951 M/40 calcium chloride.
4.
Thromboplastin ; this is prepared from rabbit or human brain by the method of Quick (1951) .
All blood vessels and meninges are stripped from the brain, a piece of which is placed in a mortar and treated with acetone to dehydrate it. The material is kneaded and pressed with the pestle but grinding is avoided at this stage. The brain is extracted with three further changes of acetone and grinding may he used with the third and fourth extractions. At this stage a finely granular suspension should be readily produced. The material is spread 011 a filter paper and placed 011 a Biichner funnel. After washing repeatedly 011 the funnel with acetone the material is dried bv suction and subsequently at 37?C. for 30 minutes. The material is stored in 0.2 g. quantities in vacuumized ampoules. For daily use the contents of one ampoule are mixed with 5 ml. saline and after incubation at f>0?C. for 20 minutes the preparation is placed in the water bath at .'?7?C. and is ready for use.
Procedure.
Venous blood is collected in a dry paraffined syringe by clean venepuncture. 4.5 ml. of blood are mixed with 0.5 ml. of oxalate or citrate. This is accomplished by the use of a graduated centrifuge tube or other marked test tube, ensuring thorough gentle mixing of blood and anticoagulant.
To 0.2 ml. of plasma in a small tube of standard size is added 0. (Quick 1951 Using dicoumarol under optimal conditions bleeding is of minor degree and relatively uncommon (Allen, 1947) . Under similar conditions, the use of tromexan may be even less liable to produce bleeding, so that, in the absence of a potential source of haemorrhage and of the other contraindications previously discussed, the incidence of even minor haemorrhagic complications can be expected to be under 3 per cent. Severe haemorrhage is a rarity and an indication of faulty therapeutic control.
Tromexan has an unpleasant taste and occasionally is associated with nausea and vomiting.
Antidotes to dicoumarol and tromexan. Blood transfusion and the administration of vitamin K preparations are earried out when it is desired to hasten the return of therapeutic hypoprothrombinaemia towards normal.
The first of these is undoubtedly effective, and the blood need not be freshly withdrawn from the donor. The use of lyophil-dried plasma has been favourably reported (Cosgriff et al., 1948) . It has been observed by the authors (unpublished observations, 1951) Stefanini and Pisciotta (1950) Lehmann (1942) reported that in two patients showing minor haemorrhage as a result of dicoumarol, these ' were controlled by the administration of 100-200 mg. of 2-methyl-l, 4-napthaquinone disulfate which increased the prothrombin index within 3-12 hours.' No other information is given in this or in a subsequent paper (Lehmann, 1943) in which success with a related water soluble analogue was claimed, but the relative inefficiency of the treatment was suggested by the author s statement that ' skin bruising larger than the palm of the hand should be treated with blood transfusion. ' Townsend and Mills (1942) Reconstituted lyophilized plasma can be employed as a substitute for blood but, like blood, it has a transitory effect and repeated transfusions may be necessary (Cosgriff et al., 1948 (Crafoord, 1941 
